EVIDENCE-BASED REVIEWNephroprotective Herbs in Chronic Kidney Disease:What the Research Actually Shows
- John Kim
- 3 days ago
- 10 min read
Yoon Hang “John” Kim, MD, MPH
Board-Certified Integrative Medicine | Integrative & Functional Medicine | Root Cause Medicine
KEY TAKEAWAYS
|
Introduction
Chronic kidney disease (CKD) affects roughly 10% of the global population and remains one of the leading causes of mortality worldwide, with progressively limited treatment options as the disease advances. For patients and clinicians alike, the question of whether botanical and herbal therapies can meaningfully slow renal decline is both important and understandably fraught with uncertainty.
As an integrative medicine physician, I am often asked about the role of herbs in kidney protection. The honest answer is nuanced: there is a growing body of evidence—including randomized controlled trials—suggesting that certain botanicals can complement standard nephrology care, but the evidence is not yet robust enough to replace guideline-directed therapy. This article surveys the most well-studied nephroprotective herbs, examines what clinical data actually exists, and offers practical considerations for safe integration.
A note on terminology: “Nephroprotective” in this context refers to demonstrated ability to reduce proteinuria, slow estimated glomerular filtration rate (eGFR) decline, lower serum creatinine (SCr) and blood urea nitrogen (BUN), and/or mitigate the inflammatory and fibrotic pathways that drive kidney disease progression.
Individual Herbs with the Strongest Renal Evidence
1. Astragalus membranaceus (Huang Qi)
Astragalus is arguably the most extensively studied single herb for kidney protection, with data spanning Cochrane reviews, meta-analyses, and now a significant multicenter RCT.
Mechanism of action: The root contains bioactive saponins (notably astragaloside IV), flavonoids, and polysaccharides that exert anti-inflammatory, anti-fibrotic, antioxidant, and immunomodulatory effects. Preclinical data demonstrate activity through the TGF-β/Smad signaling pathway (a central fibrosis driver), NF-κB-mediated inflammatory cascades, and AMPK signaling. A 2024 systematic review and meta-analysis of 40 animal studies involving 1,543 animals confirmed significant reductions in SCr, BUN, urinary albumin excretion, and histological injury markers, along with improved antioxidant status and reduced fibrosis biomarkers (TGF-β1, CTGF, collagen IV) [12].
Clinical evidence: The landmark 2024 multicenter, assessor-blind RCT by Chan et al. enrolled patients with type 2 diabetes, stage 2–3 CKD, and macroalbuminuria (ClinicalTrials.gov: NCT03535935). Participants receiving add-on astragalus (15 g/day as granules) for 48 weeks showed a significantly slower eGFR decline—a difference of 4.6 mL/min/1.73m² per year (95% CI: 1.5–7.6, p = 0.003) compared with standard care alone. The astragalus group also demonstrated a 7.9 mmHg reduction in systolic blood pressure. Adverse events were comparable between groups [2].
A 2014 Cochrane review found that astragalus as an adjunct to conventional therapy showed promising effects on reducing proteinuria and increasing hemoglobin and serum albumin, though the authors noted that suboptimal methodological quality across included studies precluded definitive conclusions [3]. A smaller self-controlled case series from Keio University Hospital in Japan (2022) reported statistically significant eGFR improvements in 37 patients with mild-to-moderate CKD after approximately 3.4 months of astragalus-containing herbal preparations [4].
Clinical takeaway: Among single-herb interventions, astragalus currently has the strongest clinical evidence for slowing CKD progression, particularly in the context of diabetic kidney disease. The 2024 RCT data are encouraging, though larger confirmatory trials are needed.
2. Cordyceps sinensis (Dong Chong Xia Cao)
Cordyceps has been used in traditional Chinese medicine for centuries as a kidney and lung tonic. In modern clinical practice, fermented preparations (Bailing capsules, Jinshuibao capsules) are the most commonly studied formulations.
Mechanism of action: Cordyceps contains cordycepin, polysaccharides, and ergosterol derivatives that exhibit anti-inflammatory, immunomodulatory, and anti-fibrotic properties. It has been shown to modulate PI3K/Akt and TGF-β/Smad pathways, reduce oxidative stress, and improve renal microcirculation [1, 6].
Clinical evidence: Meta-analytic data suggest that adjunctive Cordyceps products reduce SCr, BUN, 24-hour urinary protein, and inflammatory markers when combined with standard CKD therapy. A 2025 narrative review summarized that Cordyceps offers a multifaceted approach in diabetic kidney disease beyond what conventional therapies targeting hyperglycemia, hypertension, and proteinuria alone can achieve [1]. However, most individual trials are small and methodologically limited.
3. Salvia miltiorrhiza (Danshen)
Danshen is a cornerstone of traditional Chinese cardiovascular and renal formulas. Its primary bioactive constituents include tanshinones and salvianolic acids.
Mechanism of action: Salvia miltiorrhiza activates blood circulation in TCM terms; in modern pharmacological language, it provides anticoagulant, anti-inflammatory, anti-fibrotic, and antioxidant effects. It targets NF-κB signaling, reduces TGF-β1 expression, and improves renal microvascular perfusion [1, 6].
Clinical evidence: Danshen appears most frequently as a component of multi-herb formulas rather than as a single-agent therapy for CKD. Its inclusion in formulas targeting proteinuria and renal fibrosis is well documented, though isolating its independent contribution remains challenging.
4. Rheum officinale (Da Huang / Rhubarb Root)
Rhubarb root has a long history of use in Chinese medicine for kidney disease, particularly for managing uremic toxin accumulation.
Mechanism of action: Rhubarb contains anthraquinone glycosides (emodin, rhein, chrysophanol), flavonoids, and stilbene glycosides. Its nephroprotective action operates primarily through enhanced uremic toxin excretion via the colon and suppression of renal interstitial fibrosis. It essentially functions as a botanical approach to gut-kidney axis modulation—a concept that has gained significant traction in mainstream nephrology [1, 10].
Clinical evidence: A systematic review and meta-analysis of 34 clinical studies involving 2,786 patients demonstrated that rhubarb-containing formulas significantly reduced SCr, BUN, and uric acid levels while increasing creatinine clearance rates. The magnitude of benefit was modest but consistent across studies [1].
Safety note: The anthraquinone fraction carries dose-dependent risks including gastrointestinal effects and potential nephrotoxicity with prolonged high-dose use. Standardized extraction methods can mitigate these concerns by removing problematic compounds while retaining therapeutic activity [10].
5. Other Notable Botanicals
Curcumin (Curcuma longa): Clinical data in CKD patients demonstrate reductions in proteinuria and oxidative stress markers. A combination of Curcuma longa with Boswellia serrata showed decreased inflammatory cytokines in CKD patients [10]. Bioavailability remains a practical limitation without enhanced formulations.
Tripterygium wilfordii Hook F (Lei Gong Teng): Multi-glycoside extracts show potent immunosuppressive and anti-proteinuric effects, particularly in IgA nephropathy and membranous nephropathy. However, this herb has a narrow therapeutic window with significant risks of nephrotoxicity, hepatotoxicity, and reproductive toxicity if misused. It requires expert supervision and close lab monitoring [1, 6].
Urtica dioica (Stinging Nettle): Preclinical data show attenuation of tubular atrophy, glomerular shrinkage, and tubulointerstitial fibrosis. Some clinical benefit has been observed in patients undergoing partial nephrectomy or transplantation, though larger trials are lacking [10].
Multi-Herb TCM Formulas: The Formula Approach
Traditional Chinese medicine typically uses herbs in combination rather than isolation, based on the principle that synergistic formulations targeting multiple pathological pathways simultaneously can provide broader therapeutic coverage. Several multi-herb formulas have accumulated meaningful clinical data for kidney protection.
Formula | Indication / Context | Key Evidence |
Chinese Herbal Formula Granules (Jiangsu CKD Trial) | CKD Stage 3 | Multicenter double-blind RCT (n=343): Improved eGFR and lower SCr vs placebo after 24 weeks on top of standard care [7] |
Tangshen Formula (TSF) | Diabetic Kidney Disease | Multicenter double-blind RCT: Reduced 24-h urinary protein, improved symptoms, delayed progression. Mechanistic data showing NF-κB and TGF-β/Smad3 pathway suppression [5] |
Shenzhuo Formula (SZF) | Proteinuric CKD | RCT vs irbesartan: Non-inferior proteinuria reduction with better eGFR preservation and TCM symptom improvement [8] |
Classical Tonifying Formulas (Liuwei Dihuang, Zhenwu, Shen-Qi-Wan, Yu-Quan-Wan) | CKD and DKD (by syndrome differentiation) | Preclinical and small clinical studies suggesting improved renal function and reduced proteinuria, particularly in kidney-yang or kidney-yin deficiency presentations [1, 6] |
A notable large-scale observational study from Taiwan reported that CKD patients using Chinese herbal medicine under experienced TCM physicians showed improved long-term survival over a 12-year follow-up period compared with non-users, though the authors appropriately acknowledged that confounding and selection bias cannot be fully excluded from a retrospective cohort design [9, 16].
Shared Mechanistic Pathways
What makes the nephroprotective herb literature compelling is the convergence of multiple botanical agents on the same fundamental pathological pathways that drive CKD progression:
Inflammation: Multiple herbs suppress NF-κB signaling, reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) that perpetuate glomerular and tubulointerstitial injury.
Fibrosis: TGF-β/Smad3 pathway inhibition is a recurring theme across astragalus, Tangshen Formula, danshen, and rhubarb derivatives—directly targeting the central fibrosis cascade.
Oxidative stress: Enhanced antioxidant enzyme activity (SOD, catalase) and reduced lipid peroxidation are consistently demonstrated across multiple agents.
Gut-kidney axis: Rhubarb and certain formulas enhance intestinal excretion of uremic toxins, a mechanism that aligns with emerging mainstream interest in the gut microbiome’s role in CKD progression.
Hemodynamic effects: Blood pressure reduction (as seen with astragalus) and improved renal microvascular perfusion (danshen) provide additional renoprotective benefit independent of the molecular pathways above.
Safety Considerations and Integration Principles
The responsible integration of nephroprotective herbs into a CKD management plan requires attention to several critical safety principles. This is not a domain for self-prescribing or casual supplementation.
Herb-drug interactions: Patients with CKD are typically on multiple medications (ACE inhibitors, ARBs, SGLT2 inhibitors, diuretics, phosphate binders, ESAs). Many herbal preparations can interact with these agents, affecting drug metabolism, potassium levels, or anticoagulation status. The National Kidney Foundation emphasizes that herbal supplements are not held to the same regulatory standards as pharmaceuticals in the United States and may contain contaminants, undeclared ingredients, or inconsistent dosing [14].
Narrow therapeutic window herbs: Tripterygium wilfordii is the most notable example—potent anti-proteinuric effects but real risks of hepatotoxicity, nephrotoxicity, and reproductive harm at inappropriate doses. This herb should only be used under direct supervision of an experienced practitioner with regular hepatic and renal monitoring.
Standardization: One of the persistent challenges in herbal medicine research is batch-to-batch variability. Granule preparations and standardized extracts (as used in the Chan et al. astragalus RCT) offer more consistent pharmacological profiles than raw herb decoctions.
The adjunctive principle: The best-supported clinical use of nephroprotective herbs is as an add-on to evidence-based nephrology care—not a replacement for it. RAASi, SGLT2 inhibitors, blood pressure optimization, glycemic control, and dietary management remain the foundation. Herbs are layered on top, with regular labs (eGFR, UACR, electrolytes, liver function) and coordination between nephrologist and experienced herbal or integrative practitioner.
PRACTICAL INTEGRATION CHECKLIST
|
Honest Assessment: Where We Stand
Systematic reviews in diabetic kidney disease consistently indicate that Chinese herbal medicine formulas combined with conventional therapy may further reduce albuminuria and improve renal function beyond standard care alone. However, the overall evidence quality remains low to moderate, with significant heterogeneity in formula composition, trial methodology, outcome measures, and follow-up duration.
The most common methodological limitations across this literature include: lack of adequate blinding, short study durations (many trials are 12–24 weeks), inconsistent formula standardization, small sample sizes, and a paucity of hard endpoints (dialysis initiation, transplantation, mortality) as opposed to surrogate markers like eGFR and proteinuria.
That said, the trajectory of evidence is encouraging. The 2024 astragalus RCT by Chan et al. represents a meaningful step forward in study quality, and larger confirmatory trials are in various stages of planning and execution. The convergence of multiple herbs on established pathological pathways (TGF-β, NF-κB, oxidative stress) lends biological plausibility to the clinical signals we are observing.
Conclusion
The field of nephroprotective herbal medicine is maturing from anecdotal tradition and small pilot studies toward a more rigorous evidence base. Astragalus, Cordyceps, Danshen, rhubarb, and several well-characterized multi-herb formulas have demonstrated meaningful signals of renal protection through anti-inflammatory, anti-fibrotic, antioxidant, and gut-kidney axis mechanisms.
For patients and clinicians willing to integrate these agents thoughtfully—adjunctively, with standardized preparations, under close monitoring, and in coordination with the nephrology team—there is reason for cautious optimism. The key word is “cautious.” We are dealing with complex, progressive disease in patients often on multiple medications, and the safety framework must match the clinical complexity.
As always, the best medicine is individualized, evidence-informed, and rooted in the fundamental principle of doing no harm while leaving no reasonable therapeutic avenue unexplored.
This article is for educational purposes and does not constitute medical advice. Patients with CKD should work closely with their healthcare team before initiating or modifying any herbal therapy. Dr. Kim is board-certified in integrative medicine, preventive medicine, and medical acupuncture. For clinical consultations, visit www.directintegrativecare.com.
References
1. Tsai Y, Tsai C, Lin Y, Chang H, Kuo C. Chinese Herbal Medicine in the Treatment of Chronic Kidney Disease: A Narrative Review. Iran J Pharm Res. 2025;24(1):e165904.
2. Chan KW, Kwong ASK, Tsui PN, et al. Add-on astragalus in type 2 diabetes and chronic kidney disease: A multi-center, assessor-blind, randomized controlled trial. Phytomedicine. 2024;130:155457.
3. Zhang HW, Lin ZX, Xu C, Leung C, Chan LS. Astragalus (a traditional Chinese medicine) for treating chronic kidney disease. Cochrane Database Syst Rev. 2014;2014:CD008369.
4. Ogawa-Ochiai K, Oikawa K, et al. Oral Astragalus Root Supplementation for Mild to Moderate Chronic Kidney Disease: A Self-Controlled Case-Series. Front Pharmacol. 2022;13:775798.
5. Li P, Chen Y, Liu J, et al. Efficacy and Safety of Tangshen Formula on Patients with Type 2 Diabetic Kidney Disease: A Multicenter Double-Blinded Randomized Placebo-Controlled Trial. PLoS ONE. 2016;11(5):e0147693.
6. Zhong Y, Deng Y, Chen Y, Chuang PY, He JC. Therapeutic Use of Traditional Chinese Herbal Medications for Chronic Kidney Diseases. Kidney Int. 2013;84(6):1108-1118.
7. Chen Q, Zhang Y, et al. Chinese Herbal Formula Granules for CKD Stage 3: A Multicenter Double-Blind RCT. Evid Based Complement Alternat Med. 2020;2020:4073901.
8. Chen YQ, et al. Shenzhuo Formula for Proteinuric CKD: A Randomized Controlled Trial vs Irbesartan. Precis Clin Med. 2024;8(4):pbaf031.
9. Huang KC, Su YC, Sun MF, Huang ST. Chinese Herbal Medicine Improves the Long-Term Survival of Patients with Chronic Kidney Disease: A 12-Year Cohort Study. Front Pharmacol. 2018;9:1117.
10. Piccoli GB, Alrukhaimi M, Liu ZH, Cosber C, Jha V. Promoting Plant-Based Therapies for Chronic Kidney Disease. J Ren Nutr. 2022;32(6S):S57-S64.
11. Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96(6):414-422.
12. Chan KW, et al. Renal protective effects and mechanisms of Astragalus membranaceus for diabetic kidney disease: An updated systematic review and meta-analysis. J Ethnopharmacol. 2024;327:117877.
13. Sun L, et al. Nephroprotective effects of substances of medicine food homology and traditional Chinese medicine phytochemicals against acute kidney injury. Front Pharmacol. 2025;16:1539886.
14. National Kidney Foundation. Herbal Supplements and Kidney Disease. kidney.org. Accessed 2025.
15. Veronese FV, et al. Nephroprotective Plant Species Used in Brazilian Traditional Medicine for Renal Diseases: Ethnomedical, Pharmacological, and Chemical Insights. Pharmaceuticals (Basel). 2025;18(3):393.
16. Lin MY, Chiu YW, et al. Chinese herbal medicine use associated with improved long-term survival in CKD patients: A population-based cohort study. Front Pharmacol. 2018;9:1117.
Comments